Browsing by Subject "Human Papillomavirus"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women
    (Wiley, 2013-10) Tong, Yan; Ermel, Aaron; Tu, Wanzhu; Shew, Marcia; Brown, Darron R.; Department of Biostatistics, Richard M. Fairbanks School of Public Health
    Antibodies directed against the human papillomavirus (HPV) L1 protein are detected in approximately 70% of individuals with HPV infections. The factors associated with a serological response are not characterized. It is hypothesized that the HPV viral load, duration of detection, or both would be associated with seropositivity in adolescent women. Adolescent women (n = 117), ages 15-17 at enrolment were followed for a mean of 6.2 years. Quarterly vaginal swabs (mean 22 per participant) were used to identify HPV 6, 11, 16, or 18 DNA (Roche PCR/Linear Array). Type-specific HPV infection was defined as ≥2 positive assays. To approximate viral load, Roche PCR/Linear Array test strips were scored visually based on the strength of signal relative to beta-globin controls. Sera collected near the end of study were tested by cLIA. Regression models were fit to assess associations between strength of signal (as represented by mean and cumulative strength of signal), duration of HPV detection, seropositivity, and serotiter. Detection of HPV DNA was associated with seropositivity for four types combined and for types 6, 16, and 18. Overall, 70.1% of DNA positive episodes were associated with type-specific seropositivity. The cumulative HPV DNA signal strength during periods of HPV detection for types 6, 11, 16, and 18 combined was associated with seropositivity (OR = 1.21, 95% CI 1.02-1.44 P = 0.026). No other HPV DNA predictors were found to be associated with seropositivity or serotiter.
  • Thumbnail Image
    Item
    Center for HPV Research at IUPUI
    (Office of the Vice Chancellor for Research, 2013-04-05) Zimet, Gregory; Fortenberry, J. Dennis; Buckley, Katherine E.
    Human Papillomavirus (HPV) infection is highly prevalent among women and men and is associated with a number of diseases including genital warts, cervical cancers, other anogenital cancers in both men and women, and cancers of the head and neck. HPV infections are also associated with millions of dollars in annual health care costs. Two vaccines have been developed to prevent HPV infection. Both are approved for use in females ages 9 through 26, and one vaccine is approved for use in 9 to 26 year old males as well. Both vaccines are efficacious, safe, and cost-effective. Despite the great promise of HPV vaccines, vaccination rates in the U.S. are much lower than desired, with 2011 data indicating that 53% of 13-17 year old females received one or more doses and only 37% completed the 3-dose series. The ongoing medical, psychosocial, and financial costs of HPV infection indicate the need for comprehensive, cross-disciplinary research efforts coordinated with community outreach. We have established the Center for Human Papillomavirus (HPV) Research at IUPUI; which fosters cohesion and collaboration among investigators from multiple disciplines and departments at IUPUI, IU Bloomington, and University of Notre Dame pursuing HPV-related research. This group of accomplished senior faculty and promising junior scholars represents a growing synergy between basic, clinical, and social/behavioral sciences. The Center for HPV Research will provide formal infrastructure and resources for pilot research projects, and a collaborative environment for development of proposals for external funding. By capitalizing on the unique strengths of an internationally recognized faculty and IUPUI’s remarkable culture of collaborative and interdisciplinary research, we will establish a world-class center for HPV research, research training, and research translation. The overall mission of the Center for HPV Research will be to improve understanding of HPV transmission, infection, and prevention of HPV infection and its consequences.
  • Thumbnail Image
    Item
    Efficacy of tailored messages to improve behavioral intent to accept HPV vaccination among mothers may be moderated by sociodemographics
    (Elsevier, 2021-05-29) Feemster, Kristen A.; Head, Katharine J.; Panozzo, Catherine A.; O'Dell, Sean M.; Zimet, Gregory D.; Kornides, Melanie L.; Pediatrics, School of Medicine
    We assessed differences in response to a tailored recommendation intervention for HPV vaccine by participants’ sociodemographic characteristics in this exploratory sub-analysis of a larger web-based, randomized-controlled trial on tailored messaging among mothers with low intent to vaccinate their 11–14-year-old child against HPV. The intervention consisted of pre-recorded video messages tailored to 1–5 common concerns about HPV vaccine. In these exploratory analyses, we used generalized linear models to assess differences in post-intervention intent across intervention arms, stratified by sociodemographic characteristics among 496 trial participants. We found significantly higher post-intervention intent in the intervention participants versus the control group among mothers: 1) with younger children; 2) with white vs. black children; 3) with Non-Hispanic children; 4) who were younger; 5) with some college or vocational training; with household incomes of ≥$100,000; and 7) with 1–2 children. Our findings of effect modification by certain sociodemographic factors such as age, race/ethnicity, and household income should be considered when designing similar tailored messaging interventions.
  • Thumbnail Image
    Item
    Human Papillomavirus Vaccine Initiation for Adolescents Following Rhode Island’s School-Entry Requirement, 2010–2016
    (American Public Health Association, 2018-10-01) Thompson, Erika L.; Livingston, Melvin D.; Daley, Ellen M.; Zimet, Gregory D.; Pediatrics, School of Medicine
    Objectives. To assess changes in human papillomavirus (HPV) vaccine initiation for adolescent girls and boys in Rhode Island compared with all other states. Methods. We estimated the gender-specific effects of Rhode Island’s school-entry HPV vaccination policy on self-reported HPV vaccination initiation by using a difference-in-differences design with the National Immunization Survey–Teen from 2010 through 2016. Results. Compared with boys in other states, boys in Rhode Island increased their HPV vaccine initiation rate by 11% (b = 0.11; 95% confidence interval [CI] = 0.05, 0.18) after enactment of the requirement. No difference was seen in the probability of HPV vaccine initiation among girls in Rhode Island compared with girls in the multistate control (b = −0.01; 95% CI = −0.08, 0.05). Conclusions. Our analysis identified an 11% increase in HPV vaccine initiation rate among boys in Rhode Island after the school-entry requirement was enacted, whereas no significant change was observed for girls. Public Health Implications. Given suboptimal vaccine uptake rates in the United States, continued pursuit of state-level public policy to improve HPV vaccination is needed. School-entry requirements for HPV vaccination may be a strategy for closing the gap in HPV vaccine uptake for boys and girls.
  • Thumbnail Image
    Item
    Implementation of New Technology to Reduce and or Eliminate Human Papillomavirus to Improve Probe Disinfection
    (2018-04-30) Jones, Ericka; Christe, Barbara
    The project detailed in this report defines the implementation of a new technology at the Christ Hospital Network that would cause for the removal of the current Glutaraldehyde User Station's (GUS) soaking station to be replaced with the Trophon systems. By implementing the new technology, this would improve probe disinfection and reduce the risk of patient Human papillomavirus (HVP) from probe related hospital acquired infections. The problem was that the Christ Hospital Network used GUS disinfection soak stations (G10VP) to perform high level disinfection on intracavity probes in the Emergency Department, General Ultrasound, and Outpatient Obstetrician and Gynecology areas. This product is not approved to kill the human papillomavirus (HPV). Studies have proven HPV can be passed from one person to another via intracavity or surface ultrasound probes, if probes are not adequately disinfected before use (Nanosonics, 2015). Common disinfection methods, even high level disinfection (HLD) methods, do not kill the cancer-causing HPV on ultrasound probes. The HPV virus can survive and remain infectious on surfaces, including medical equipment, for days or weeks, when treated with common disinfectants (Nanosonics, 2015). Results show that Trophon Environmental Probe Reprocessor (EPR) was the only disinfectant to completely inactivate HPV (Nanosonics, 2015). This project required removal of all existing GUS soak stations (G10VP) from the aforementioned departments, and replaced with new Trophon probe high level disinfection systems. Staff reeducation was performed, and changes were made to hospital policy and process. The final part of this project was the Biomed training, so that the Healthcare Technology Management department was ready to take over and handle any service related problem through the duration of ownership by the hospital. Preface This project was design to fulfill my graduation requirements for my Bachelors of Science at IUPUI. As part of the requirements, I completed the project planning and design course, HETM-49000. As a part of the course, I had to compose a written proposal and present it to my place of employment for approval. I proposed the implementation of a new technology at the Christ Hospital Network called Trophon systems. Implementation of the new technology would improve probe disinfection and reduce the risk of patient Human papillomavirus (HVP) infection from probe related hospital acquired infections. The final step of my undergraduate degree was to complete the senior capstone project course HETM 49200. This course required that I manage the work, set the pace, and meet the posted deadline. This imposed a great deal of stress on me, because I knew my graduation was dependent on me successfully completing this course. My project idea became an interest to me after Penn State released the findings of a study they conducted proving that Human papillomavirus (HVP) is not being killed by our current probe disinfection system. I would like to acknowledge and thank first my family for being supportive of my dreams and goals. I would like to thank Dr. Barbara Christe, for always offer encouragement when it was needed. Being a student at IUPUI has helped me grow and develop academically, professionally and personally. I learned my strengths are things I leverage on, and things I use to push myself further when I wanted to give up. On the other hand I was able to recognize my weakness that I will continue to develop and build upon. Lastly I would like to offer a heartfelt thank you to the amazing staff at The Christs Hospital Network for embracing change and wanting to continuing to do what is necessary to stay a leader in the healthcare industry.